Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Johnson & Johnson (J&J) has reported positive topline outcomes from the Phase III MARIPOSA trial of Rybrevant ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

In this edition of InnovationRx, medical debts will be erased from credit histories, this farm is doubling down on raw milk ...

FDA grants priority review tag to JNJ's nipocalimab BLA for gMG and asks for new warnings on GSK & PFE's RSV vaccine labels.

Dame Esther responded after a columnist tried to use her own cancer experience as an argument against assisted dying.

Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...

The other day, Dame Esther Rantzen announced some wonderful news. In an article she’d written for a national newspaper, ...

Cullinan Therapeutics’ strong financial position funds growth into 2028. Find out why CGEM stock presents a compelling buy ...

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetrationEnrolling ...

Johnson & Johnson released results from a phase 3 study, showing that the combination of Rybrevant and Lazcluze significantly improved overall survival in patients with advanced non-small cell lung ...